RxDoctor Payments Data

Tracy Roberts, NP

Family · Meridian, IDNPI 1396369138

Payments from drug & device makers

$3,063in general payments, 2019–2025

Across 127 payments — averaging $24.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$640
  • AbbVie$305
  • Neurocrine Biosciences, Inc.$302
  • AstraZeneca$208
  • Otsuka America Pharmaceutical, Inc.$158
  • Lilly USA, LLC$158
  • plus $1K from 30 others

What the payments were for

  • Food & beverage$3,00398%
  • Education$602%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,063 in reported general payments places this provider in the 90th percentile of 809 family providers in Idaho.

See all family providers in Idaho

Medicare billing

Part B allowed, 2024
$775,978
Medicare patients
175
Services billed
2,777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban215$139,266
MyrbetriqMirabegron53$24,537
JardianceEmpagliflozin18$15,468
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$14,514
RestasisCyclosporine32$13,351
Potassium Chloride278$11,412
TrulicityDulaglutide12$10,560
XareltoRivaroxaban14$8,281
FarxigaDapagliflozin Propanediol12$6,920
AbrysvoRsv Vacc, Pref A And Pref B/Pf21$6,418
Sucralfate41$6,390
Lantus SolostarInsulin Glargine,hum.Rec.Anlog67$6,205
Memantine Hcl ErMemantine Hcl36$5,755
Levothyroxine Sodium575$5,593
Fluticasone-SalmeterolFluticasone Propion/Salmeterol35$5,344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$131$145,683236 claims
Boehringer IngelheimJardiance$57$15,46818 claims
GSKTrelegy Ellipta$40$14,51421 claims
AbbVieRestasis$305$13,35132 claims
Lilly USA, LLCTrulicity$158$10,56012 claims
Johnson & JohnsonXarelto$93$8,28114 claims
AstraZenecaFarxiga$208$6,92012 claims
Sanofi-aventis U.S. LLCLantus$16$2,25711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 809 family providers in Idaho.

Other family in Meridian

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →